CMA tops Q2 earnings estimates as NII jumps nearly 8% and loan balances climb, despite asset quality concerns.

CNBC's Hugh Son joins 'Money Movers' to discuss takeaways from American Express' earnings call.

StepStone Group (STEP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Pre-market futures are up again as a very eventful trading week winds to a close. The Dow is currently +0.12%, the S&P 500 is +0.09% and the Nasdaq +0.16% at this hour.

Regions Financial Corp.'s investments in technology and talent drove 10% year-over-year growth in revenue in the second quarter, bringing the regional bank's total revenue for the quarter to $1.9 billion, according to a Friday (July 18) earnings release.

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.

F.N.B. Corporation (NYSE:FNB ) Q2 2025 Earnings Conference Call July 18, 2025 8:30 AM ET Company Participants Christopher Chan - Executive VP & Chief Strategy Officer of First National Bank of Pennsylvania Gary Lee Guerrieri - Chief Credit Officer Lisa Hajdu - Corporate Participant Vincent J. Calabrese - Chief Financial Officer Vincent J.

Rick Wurster, Charles Schwab CEO, joins 'Money Movers' to discuss the company's earnings, what's contributing to growth and the impact of crypto.

Here is what you may have missed on Morning Brief on Friday, July 18. Federal Reserve governor Christopher Waller says he would like to see the central bank cut rates at its July meeting, putting him in conflict with other FOMC members who want to wait on cuts.

Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revised downward. The impending approval of a rival therapy in the advanced melanoma space - Replimmune's RP1 - is another cause for concern.

QQQI piqued my interest as rising NASDAQ valuations make covered-call funds attractive. But I see better alternatives such as QYLD and JEPQ. Compared to these funds, QQQI has higher fees and lower liquidity.

KLA stock and Quanta Services both flashed new buy points after big moves higher.

TSM's blowout Q2 performance fuels gains for ETFs like SPWO, SPTE, SMH, MEMX, and EMM, all heavily exposed to the AI chip leader.

WBS stock climbs after Q2 earnings top forecasts, fueled by rising fee income, NII and improved profitability.

The slumping greenback will be a key tailwind to second-quarter earnings.

Paul Sankey, Sankey Research lead analyst, joins 'Money Movers' to discuss Chevron closing on the Hess acquisition and what it means for the company and on the oil sector.

Sprouts Farmers Market is delivering impressive growth in revenue, profitability, and store count, with strong digital and private label expansion. Despite robust fundamentals and a net cash position, I view shares as expensive both absolutely and relative to peers, limiting upside. Management's aggressive growth plans and loyalty initiatives are promising, but valuation remains a concern even with optimistic guidance.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

DENVER, July 18, 2025 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading provider of SaaS solutions for service SMBs, will report its second quarter 2025 financial results after the U.S. financial markets close on Thursday, August 6, 2025. Management will host a conference call on Wednesday, August 6 at 5:00 p.m.

LOS ANGELES, July 18, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between November 3, 2022 to April 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.